Amgen Inc. $AMGN Shares Sold by American National Bank & Trust

American National Bank & Trust cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,093 shares of the medical research company’s stock after selling 1,906 shares during the quarter. Amgen accounts for 1.2% of American National Bank & Trust’s investment portfolio, making the stock its 26th largest position. American National Bank & Trust’s holdings in Amgen were worth $13,949,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Rational Advisors Inc. increased its stake in Amgen by 13.7% in the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock valued at $72,000 after purchasing an additional 24 shares during the last quarter. Beacon Financial Advisory LLC raised its stake in Amgen by 2.0% during the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after purchasing an additional 25 shares during the period. Legacy Financial Advisors Inc. grew its stake in shares of Amgen by 0.8% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after buying an additional 26 shares during the period. Roman Butler Fullerton & Co. boosted its holdings in Amgen by 1.4% in the second quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock valued at $705,000 after acquiring an additional 27 shares during the last quarter. Finally, Round Rock Advisors LLC increased its stake in Amgen by 2.9% during the second quarter. Round Rock Advisors LLC now owns 1,003 shares of the medical research company’s stock worth $363,000 after acquiring an additional 28 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

NASDAQ AMGN traded up $10.57 during trading hours on Wednesday, reaching $413.17. The company’s stock had a trading volume of 939,280 shares, compared to its average volume of 2,751,854. The stock has a market cap of $223.37 billion, a PE ratio of 25.68, a PEG ratio of 2.91 and a beta of 0.41. The business has a 50-day simple moving average of $411.44 and a 200 day simple moving average of $371.01. Amgen Inc. has a 52 week low of $288.00 and a 52 week high of $447.03. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same period last year, the business posted $6.02 earnings per share. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts predict that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were paid a dividend of $2.52 per share. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.4%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 over the last quarter. Insiders own 0.85% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported that its AMG 513 obesity-drug study completed Phase 1. The milestone provides an additional potential growth opportunity in the competitive weight-loss market, although clinical efficacy and safety data remain important next steps. Amgen AMG 513 obesity trial article
• Positive Sentiment: Scotiabank raised its price target for Amgen from $450 to $500, signaling greater confidence in the company’s upside potential and supporting sentiment around the stock. Scotiabank raises Amgen price target
• Neutral Sentiment: Truist raised its target from $362 to $380 but maintained a Hold rating. The revised target remains below the recent trading level, limiting the bullish impact of the increase.
• Neutral Sentiment: Cantor Fitzgerald reiterated a Neutral rating, while another report cited a $400 target. These views suggest analysts see limited near-term upside after Amgen’s strong run. Cantor Fitzgerald Amgen rating
• Neutral Sentiment: Amgen has become a heavily watched or “trending” stock on Zacks, which may increase trading attention but does not represent a fundamental change in the company’s outlook. Zacks Amgen trending stock article
• Negative Sentiment: Morgan Stanley lowered its target from $362 to $359 and retained an Equal Weight rating. The target implies substantial downside from current levels, reinforcing concerns that expectations and valuation may be elevated. Morgan Stanley Amgen price target report

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AMGN. Sanford C. Bernstein raised their target price on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Truist Financial boosted their price target on Amgen from $362.00 to $380.00 and gave the stock a “hold” rating in a research report on Wednesday. Barclays lifted their price objective on shares of Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Argus raised their price target on shares of Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Finally, Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $385.79.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.